Azomycin (BioDeep_00001871741)

Main id: BioDeep_00000009958

 

Chemicals and Drugs


代谢物信息卡片


2-Nitroimidazole

化学式: C3H3N3O2 (113.0225258)
中文名称: 2-硝基咪唑
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CN=C(N1)[N+](=O)[O-]
InChI: InChI=1S/C3H3N3O2/c7-6(8)3-4-1-2-5-3/h1-2H,(H,4,5)

描述信息

Azomycin (2-Nitroimidazole) is an antibiotic which can be active against aerobic Gram-positive and Gram-negative bacteria.

同义名列表

3 个代谢物同义名

2-Nitroimidazole; 1-nitroimidazole; Azomycin



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

2 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Jinglei Du, Lin Zhu, Xue Zhou, Wei Yin, Aifang Deng, Jinping Qiao. Dose-response relationships of FMISO between trace dose and various macro-doses in rat by ultra-performance liquid chromatography with mass spectrometry and radioactivity analysis. Journal of pharmaceutical and biomedical analysis. 2012 Nov; 70(?):499-504. doi: 10.1016/j.jpba.2012.07.016. [PMID: 22867691]
  • Zhihao Zha, Lin Zhu, Yajing Liu, Fenghua Du, Hongmei Gan, Jinping Qiao, Hank F Kung. Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging. Nuclear medicine and biology. 2011 May; 38(4):501-8. doi: 10.1016/j.nucmedbio.2010.11.001. [PMID: 21531287]
  • Cameron J Koch, Joshua S Scheuermann, Chaitanya Divgi, Kevin D Judy, Alexander V Kachur, Richard Freifelder, Janet S Reddin, Joel Karp, James B Stubbs, Stephen M Hahn, Jason Driesbaugh, Deborah Smith, Susan Prendergast, Sydney M Evans. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. European journal of nuclear medicine and molecular imaging. 2010 Nov; 37(11):2048-59. doi: 10.1007/s00259-010-1517-y. [PMID: 20585774]
  • C P Lee, G S Payne, A Oregioni, R Ruddle, S Tan, F I Raynaud, D Eaton, M J Campbell, K Cross, G Halbert, M Tracy, J McNamara, B Seddon, M O Leach, P Workman, I Judson. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. British journal of cancer. 2009 Dec; 101(11):1860-8. doi: 10.1038/sj.bjc.6605425. [PMID: 19935799]
  • Annamaria Buschini, Lisa Ferrarini, Susanna Franzoni, Serena Galati, Mirca Lazzaretti, Francesca Mussi, Cristina Northfleet de Albuquerque, Tânia Maria Araújo Domingues Zucchi, Paola Poli. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole. Journal of parasitology research. 2009; 2009(?):463575. doi: 10.1155/2009/463575. [PMID: 20981287]
  • Pierre Mahy, Marc De Bast, Tjibbe de Groot, Arnaud Cheguillaume, Jacques Gillart, Karin Haustermans, Daniel Labar, Vincent Grégoire. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008 Dec; 89(3):353-60. doi: 10.1016/j.radonc.2008.06.008. [PMID: 18649964]
  • P Mahy, X Geets, M Lonneux, P Levêque, N Christian, M De Bast, J Gillart, D Labar, J Lee, V Grégoire. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. European journal of nuclear medicine and molecular imaging. 2008 Jul; 35(7):1282-9. doi: 10.1007/s00259-008-0742-0. [PMID: 18317752]
  • Tomohiro Kaneta, Yoshihiro Takai, Ren Iwata, Takashi Hakamatsuka, Hiroyasu Yasuda, Katsutoshi Nakayama, Yoichi Ishikawa, Shoichi Watanuki, Shozo Furumoto, Yoshihito Funaki, Eiko Nakata, Keiichi Jingu, Michihiko Tsujitani, Masatoshi Ito, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada. Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Annals of nuclear medicine. 2007 Feb; 21(2):101-7. doi: 10.1007/bf03033987. [PMID: 17424976]
  • Steffen P Luntz, Kristina Unnebrink, Monika Seibert-Grafe, Hartwig Bunzendahl, Thomas W Kraus, Markus W Büchler, Ernst Klar, Peter Schemmer. HEGPOL: randomized, placebo controlled, multicenter, double-blind clinical trial to investigate hepatoprotective effects of glycine in the postoperative phase of liver transplantation [ISRCTN69350312]. BMC surgery. 2005 Aug; 5(?):18. doi: 10.1186/1471-2482-5-18. [PMID: 16105183]
  • P Mahy, M De Bast, P H Leveque, J Gillart, D Labar, J Marchand, V Gregoire. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3. European journal of nuclear medicine and molecular imaging. 2004 Sep; 31(9):1263-72. doi: 10.1007/s00259-004-1573-2. [PMID: 15197503]
  • H Barthel, H Wilson, D R Collingridge, G Brown, S Osman, S K Luthra, F Brady, P Workman, P M Price, E O Aboagye. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. British journal of cancer. 2004 Jun; 90(11):2232-42. doi: 10.1038/sj.bjc.6601862. [PMID: 15150578]
  • Beatrice M Seddon, Geoffrey S Payne, Laura Simmons, Ruth Ruddle, Rachel Grimshaw, Siew Tan, Alison Turner, Florence Raynaud, Gavin Halbert, Martin O Leach, Ian Judson, Paul Workman. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Nov; 9(14):5101-12. doi: NULL. [PMID: 14613987]
  • S Zoula, P F J W Rijken, J P W Peters, R Farion, B P J Van der Sanden, A J Van der Kogel, M Décorps, C Rémy. Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. British journal of cancer. 2003 May; 88(9):1439-44. doi: 10.1038/sj.bjc.6600837. [PMID: 12778075]
  • Beatrice M Seddon, Ross J Maxwell, Davina J Honess, Rachel Grimshaw, Florence Raynaud, Gillian M Tozer, Paul Workman. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Jul; 8(7):2323-35. doi: NULL. [PMID: 12114437]
  • Edward L Engelhardt, Richard F Schneider, Steven H Seeholzer, Corinne C Stobbe, J Donald Chapman. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2002 Jun; 43(6):837-50. doi: NULL. [PMID: 12050331]
  • C J Koch, S M Hahn, K Rockwell, J M Covey, W G McKenna, S M Evans. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer chemotherapy and pharmacology. 2001 Sep; 48(3):177-87. doi: 10.1007/s002800100324. [PMID: 11592338]
  • N M Najib, N Idkaidek, I E Ghanem, I Admour, S Mahmood Alam, Q Zaman, R Dham. Bioequivalence assessment of Azomycin (Julphar, UAE) as compared to Zithromax (Pfizer, USA)--two brands of azithromycin--in healthy human volunteers. Biopharmaceutics & drug disposition. 2001 Jan; 22(1):15-21. doi: 10.1002/bdd.252. [PMID: 11745903]
  • K Nemoto, Y Shibamoto, J Ohmagari, Y Baba, K Ebe, H Ariga, Y Takai, A Ouchi, K Sasai, M Shinozaki, M Tsujitani, M Sakaguchi, S Yamada, K Sakamoto. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anti-cancer drugs. 2001 Jan; 12(1):1-6. doi: 10.1097/00001813-200101000-00001. [PMID: 11272282]